--- title: "Trump administration drug-pricing plan: Did Novo Nordisk get an extra financial win?" id: "stat-news-0-stat-did-the-trump-administration-just-cut-novo-a-huge-financial-win" canonical_url: "https://medichelpline.com/clinical-feed/stat-news-0-stat-did-the-trump-administration-just-cut-novo-a-huge-financial-win" content_type: "clinical_feed_article" specialty: "Pharmacology" source_name: "STAT News" source_url: "https://www.statnews.com/2026/09/22/dc-diagnosis-did-trump-administration-cut-novo-huge-financial-win/?utm_campaign=rss" published_at: "2026-09-22T16:23:21.000Z" evidence_level: "Verified Feed" license: "CC-BY-NC-4.0 / Informational Use" --- # Trump administration drug-pricing plan: Did Novo Nordisk get an extra financial win? ## Provenance & Clinical Metadata - **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-0-stat-did-the-trump-administration-just-cut-novo-a-huge-financial-win - **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md) - **Primary Source:** STAT News - **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/09/22/dc-diagnosis-did-trump-administration-cut-novo-huge-financial-win/?utm_campaign=rss) - **Published At:** 2026-09-22T16:23:21.000Z - **Evidence Rating:** Verified Feed ## Executive GIST (TL;DR) - The Trump administration announced a drug-pricing plan intended to make medications more affordable for **Medicaid** beneficiaries; STAT reported on potential company benefits. - STAT has previously covered how Eli Lilly and **Novo Nordisk** benefited from White House deals to lower obesity drug costs for Medicare enrollees. - The new STAT story flags a possible additional concession or “sweetener” to **Novo Nordisk** tied to the administration’s plan; the article indicates Novo may have received an extra financial advantage. - The plan involves **GLP-1** weight-loss drugs in the broader discussion; STAT notes that at least some Lilly **GLP-1s** are exempt from certain MFN (most-favored-nation style) agreements. - Public commentary has included praise for GLP-1 pricing outcomes from figures such as Dr. Oz, though STAT notes that some public statements misstated which drugs are covered by the agreements. - The STAT piece includes a journalistic correction about a prior misattribution of an AEI post to a different think tank in the newsletter. - The STAT article is behind STAT+ paywall; many specifics about the alleged Novo concession and financial details were not reported in the freely available portion of the article and require subscription to read. - Where the free excerpt is silent, STAT did not report the precise nature, terms, or projected financial impact of the alleged Novo advantage in the accessible text. - STAT invited corrections and tips and provided reporter contact information for follow-up reporting requests. ## Clinical Analysis & Structured Key Points Trump drug pricing, Medicaid, Novo, GLP-1s: D.C. Diagnosis Skip to Main Content STAT Plus Newsletter D.C. Diagnosis Did the Trump administration just cut Novo a huge financial win? The White House’s GENEROUS plan was designed to make drugs more affordable for Medicaid users. There’s one glaring potential exception. Manage alerts for this article Save this story for later Share this article Andrew Harnik/Getty Images By John Wilkerson Sept. 22, 2026 Washington Correspondent John Wilkerson [email protected] John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter . You can reach John on Signal at John_Wilkerson.07. You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. Dr. Oz praised GLP-1s from Eli Lilly’s lab, where he said MFN agreements have drastically cut the price of obesity drugs. Problem is, at least Lilly’s GLP-1s are exempt from the MFN agreements (see below). But who am I to correct people? I incorrectly attributed an AEI post to another conservative think tank in this newsletter last week. Send news tips and correction requests to [email protected] or John_Wilkerson.07 on Signal. Advertisement Novo’s (potentially) big win STAT has written about how Eli Lilly and Novo Nordisk benefited from their deals with the Trump administration to cut obesity drug costs for seniors. It turns out, Novo might have gotten an additional sweetener. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Individual plans Group plans Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In drug development , Drug prices , drug pricing , Medicaid , Obesity , Policy , White House Submit a correction request Reprints John Wilkerson Washington Correspondent John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter . You can reach John on Signal at John_Wilkerson.07. Newsletter The latest updates in federal health agencies, research institutes, and U.S. policy Please enter a valid email address. Sign Up Your data will be processed in accordance with our Privacy Policy and Terms of Service . You may opt out of receiving STAT communications at any time. Recommended D.C. Diagnosis D.C. Diagnosis September 17, 2026 STAT Plus: FDA has too few staffers to hire more staff D.C. Diagnosis D.C. Diagnosis September 15, 2026 STAT Plus: RFK Jr. returns to his roots Advertisement D.C. Diagnosis D.C. Diagnosis September 10, 2026 STAT Plus: Can AI save rural health care? D.C. Diagnosis D.C. Diagnosis September 8, 2026 STAT Plus: Health care features prominently in Democrats’ agenda D.C. Diagnosis D.C. Diagnosis September 3, 2026 STAT Plus: Fauci speaks, and writes Subscriber Picks ## Related Clinical Research - [Novo and Medicare’s Bridge program: what STAT reported and what wasn’t disclosed](https://medichelpline.com/clinical-feed/stat-news-1-stat-novo-may-be-getting-a-better-deal-than-expected-with-medicare-s-bridge.md) - [Novo Nordisk outlines obesity and direct-to-consumer push, pledges five 'multi-blockbusters' by 20](https://medichelpline.com/clinical-feed/stat-news-1-stat-with-new-strategy-novo-outlines-plans-for-obesity-direct-to-consumer-work.md) - [HFpEF: Cardiac–Extracardiac Interactions and Impact of Novel Pharmacotherapies](https://medichelpline.com/clinical-feed/pubmed-42764312.md) (DOI: 10.1007/s10741-026-10671-x) - [BNT162b2 KP.2 2024–2025 Vaccine Effectiveness Against COVID-19 Hospitalization and ED/UC Visits in](https://medichelpline.com/clinical-feed/pubmed-42594639.md) (DOI: 10.1016/j.vaccine.2026.129009) - [AHA and AHS fund research on the heart–brain link in migraines and stroke risk](https://medichelpline.com/clinical-feed/aha-news-2-new-scientific-research-projects-study-heart-brain-connection-to-migraines.md) ## Navigation - [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md) - [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md) ## Medical & Regulatory Disclaimer > [!CAUTION] > MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations. > Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.